Highest-materiality recent filing
Glucotrack raises $2M via 22% OID secured convertible notes and sets 1-for-2 reverse split
Issued $2.56M principal of 8% senior secured convertible notes due 9 months for $2.0M cash, a 22% original issue discount; default rate 18%.
Glucotrack issues 406,198 new warrants at $7.50 after holders waive issuance and VRT restrictions
Glucotrack's Oct. 13, 2026 waiver with Requisite Holders ends the 90-day equity issuance restriction and warrant variable-rate price adjustment from the July 14, 2026 purchase agreement.
Lokahi merger closed July 14, 2026; 5,323,013 common-equivalent shares issued, valued at $33.33M ($6.261/share).
Glucotrack ends variable-floor adjustments on Bridge/September warrants; Bridge Notes repaid Sept 25
Bridge Warrant Amendment, Amendment No. 2 to Common Warrant and September Warrant Amendment each remove provisions permitting downward adjustment to the Floor Price.
Glucotrack announces $3.1M public offering of 169,388 shares at $2.04 and pre-funded warrants
Priced 169,388 common shares at $2.04 plus pre-funded warrants for 1,350,220 shares at $2.039.
Glucotrack (Lōkahi) advances LT-100, submits protocol; ai² platform flags 45 assets
Completed strategic business combination on July 14, 2026; Glucotrack Technologies now wholly owned subsidiary.
Glucotrack director Paul V. Goode resigns citing potential conflict of interest
Paul V. Goode resigned from Glucotrack board effective Sept. 14, 2026.
Glucotrack stockholders approve ELOC and bridge note share issuances
Special meeting Sep 11, 2026: quorum 3,661,960 shares (34.61% of 10,578,822 outstanding).
Glucotrack raises $11.6M convertible notes: $4.5M cash, rollover of existing notes
Issued $11,596,172.68 in senior secured convertible notes: $4.5M cash plus $4,545,014.69 rollover; 22% original issue discount.
Glucotrack settles Alto debt dispute with $2M cash and $2M convertible note
Settlement with Alto resolves ~$10.9M asserted debt from Apimeds Pharmaceuticals; Glucotrack and others jointly liable.
Glucotrack completes 1-for-15 reverse stock split; shares drop to ~798,144
Reverse split effective Aug 28, 2026 at 4:30 PM ET; every 15 shares became 1 share.
Glucotrack's Lokahi acquisition target: $53K cash, $8.1M H1 loss, going concern doubt
Lokahi had $53,186 cash and no revenue as of June 30, 2026; total assets $2.5M vs liabilities $9.2M.
Glucotrack announces 1-for-15 reverse stock split effective Aug 31, 2026
1-for-15 reverse split effective at market open Aug 31, 2026; shares cut from 11,972,157 to ~798,144.
Glucotrack shareholders approve 1:30 reverse split and warrant inducement at 2026 annual meeting
All six director nominees elected; votes for ranged 934,050-961,363; ~1.67M broker non-votes.
Glucotrack amends White Lion ELOC: issues 2.5M commitment shares, adds true-up provision
Amendment dated Aug 7, 2026 to July 14, 2026 ELOC with White Lion Capital, LLC.
Glucotrack raises $5.5M in combined equity and convertible debt financing
$2.0M equity PIPE at $0.75/unit: each unit includes one share (or pre-funded warrant) and a 5-year warrant at $1.50.
Glucotrack subsidiary Lokahi advances LT-100 to single-injection strategy after FDA meeting
Lokahi Therapeutics (GCTK subsidiary) plans to simplify LT-100 from 15 intradermal injections to a single subcutaneous injection per visit.
Glucotrack enters exchange agreement to convert $900K promissory note into common stock
Partitioned $900K note from existing $3.6M promissory note; balance of original note reduced accordingly.
Glucotrack enters exchange agreement to convert $900K note into common stock
On July 22, 2026, Glucotrack partitioned a $900,000 promissory note from an existing $3.6M note (reduced by prior exchanges).
Glucotrack completes reverse merger with Lokahi; existing holders get 10% floor
Lokahi shareholders receive 90% of fully diluted equity; existing Glucotrack holders get at least 10%.
Glucotrack receives second Nasdaq delisting notice; plans to appeal by May 18
First notice on May 11: non-compliance with minimum bid price of $1.00.
Glucotrack Q1 net loss $4.3M, IDE submitted to FDA for implantable CGM
Net loss $4.3M vs $6.8M YoY; cash $3.9M as of March 31, 2026.
Glucotrack submits IDE to FDA for US clinical study of implantable CBGM
Glucotrack submitted an IDE application to the FDA to initiate a US clinical study of its fully implantable continuous blood glucose monitoring (CBGM) system.
Study in Journal of Diabetes Research shows weighted average MARD of 6.8% across 79 IV glucose tolerance tests in ovine model.
Glucotrack converts $988k note into 1.3M shares, reduces debt
Exchanged a $988k partitioned promissory note for 1,300,000 common shares with an existing investor.
Glucotrack exchanges $600K promissory note for 895,000 common shares in debt-to-equity swap
Partitioned $600K from $3.6M original note and exchanged it for 895K shares of common stock.
Glucotrack reports FY2025 net loss $19.4M; cash $7.4M; plans IDE filing Q2 2026
Net loss for FY2025 was $19.4M, down from $22.6M in 2024; no product revenue.
Glucotrack to file IDE with FDA for implantable CBGM in Q2 2026, citing positive trial results
Brazil first-in-human study (Dec 2024-Jan 2025) showed MARD 7.7%, 99% data capture, and zero serious adverse events.
Glucotrack shareholders approve stock issuances for ELOC and warrants; ratify auditor
Votes: ELOC proposal: 126,610 for, 18,261 against, 7,846 abstain, 293,631 non-votes.
Glucotrack receives USPTO approval for three CBGM patents
Three US patents issued by USPTO: US 12,453,494 (Oct 28, 2025), US 12,458,257 and US 12,458,258 (Nov 4, 2025).
Glucotrack raises $4.0M via private placement of pre-funded and common warrants
Gross proceeds ~$4.0M from sale of 1,033,591 pre-funded warrants and 2,067,182 common warrants at $3.87/unit.
Glucotrack issues investor presentation; no material details disclosed
Issued an investor presentation on December 29, 2025.
Q3 2025 net loss $4.2M ($4.64 per share) vs $5.1M in Q3 2024; nine-month net loss $15.8M.
Glucotrack special meeting adjourned and cancelled due to lack of quorum
Only 17.6% of 158,370 outstanding shares were represented at reconvened meeting on Nov 7, 2025.
Glucotrack special meeting adjourned due to lack of quorum; reconvenes Nov 7
Only 16.4% of outstanding shares (899,410 total) were represented, failing to constitute a quorum.
Special Meeting reconvenes November 7, 2025 at 12 p.m. ET to vote on Equity Purchase Agreement with Sixth Borough Capital Fund LP.
Glucotrack adds Dr. Usman Latif to clinical advisory team for integrated glucose monitoring
Appoints Usman Latif, MD, MBA, a neuromodulation and PDN expert, to its clinical advisory team.
Special Meeting on October 31, 2025 at 12 p.m. ET; record date is September 23, 2025.
Glucotrack issues $3.6M convertible note at $3M price; ELOC proceeds to repay
Issued $3.6M convertible promissory note for $3M purchase price ($600K OID), no interest, due in 12 months or upon Qualified Financing.
Glucotrack signs up to $20M equity purchase agreement with Sixth Borough Capital Fund
Investor committed to buy up to $20M of common stock over 24 months at company's discretion.
Net loss of $11.6M for H1 2025 vs $7.4M prior year; operating expenses rose $0.9M.
Glucotrack appoints David S. Hirsh, MD as Medical Director, Cardiology
Dr. Hirsh, a cardiac electrophysiologist, joins Glucotrack's clinical advisory team for its CBGM program.
Glucotrack to exhibit CBGM at ADCES; touts progress toward US pilot study
Presenting at ADCES Annual Meeting Aug 8-11, 2025 in Phoenix, AZ; CBGM at Booth #1724.
Glucotrack dismisses Grant Thornton Israel as auditor, engages CBIZ CPAs effective July 18, 2025
Dismissal effective July 18, 2025; Grant Thornton reports for past two years included going-concern explanatory paragraph but no adverse opinion.
Glucotrack dismisses Grant Thornton, engages CBIZ as new auditor
Audit Committee approved dismissal of Fahn Kanne & Co. Grant Thornton Israel and engagement of CBIZ CPAs P.C., effective July 18, 2025.
Glucotrack repurchases ~49,700 Series A warrants, cuts potential dilution
Repurchased over 90% of Series A Warrants on June 30, 2025 for cash on hand in a negotiated transaction.
Glucotrack reports positive final first-in-human CBGM study results with MARD 7.7%
Study met all endpoints; MARD 7.7% across 122 matched pairs, 99% data capture, no serious adverse events.
Glucotrack executes 1-for-60 reverse stock split effective June 13, 2025
Reverse split approved by stockholders on May 22; reduces outstanding shares from 34,047,337 to ~567,456.
1-for-60 reverse stock split approved by shareholders on May 22, 2025, effective at market open on June 16, 2025.
Glucotrack to present first-in-human CBGM data at ADA 85th Scientific Sessions
Will present safety & performance data from first-in-human trial of implantable continuous blood glucose monitor (CBGM).
On September 14, 2026, Paul V. Goode notified the Board of Directors of Glucotrack, Inc. (the “Company”) of his resignation from the Board, effective immediately.
On January 27, 2025, James Cardwell informed the Board of Directors (the “Board”) of Glucotrack, Inc. (the “Company”) that he was resigning as Chief Financial Officer of the Company, effective immediately.
In connection with Mr. Cardwell’s resignation, on January 28, 2025, the Board appointed Peter C. Wulff as Chief Financial Officer of the Company.
On August 27, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Paul V. Goode, and Mr. John Ballantyne to the Board of Directors (the “Board”) as board members.
On August 27, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Paul V. Goode, and Mr. John Ballantyne to the Board of Directors (the “Board”) as board members.
On July 29, 2024, Shimon Rapp and Andrew Sycoff resigned from the board of directors.
On July 29, 2024, Shimon Rapp and Andrew Sycoff resigned from the board of directors.
On June 14, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Andrew K. Balo to the Board of Directors as an independent board member.
Effective as of October 6, 2023, Jolie Kahn resigned as Chief Financial Officer of GlucoTrack, Inc. (the “Company”) to pursue other career interests.
On October 11, 2023, the Company appointed James S Cardwell, 63, as Chief Financial Officer of the Company, effective immediately.
On August 25, 2023, the Board of Directors of GlucoTrack, Inc. appointed Erin Carter as a director to serve until her successor is elected and duly qualifies.
In connection with the Company’s previously announced plans to migrate certain aspects of product development to the United States, James P. Thrower PhD, Vice President of Engineering, will be assuming Mr. Shushan’s responsibilities.
Max materiality 1.00 · Median 0.60 · Most common event other_material